| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00296-020-04526-3 |
| P698 | PubMed publication ID | 32052146 |
| P2093 | author name string | Winfried Graninger | |
| Stephan Pflugbeil | |||
| Astrid Ortner | |||
| Karin Böckl | |||
| Marianne Leitner | |||
| Reinhold Pongratz | |||
| P2860 | cites work | Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes | Q24311331 |
| Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice | Q26798357 | ||
| Clinical pharmacokinetics of leflunomide | Q28205716 | ||
| Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations | Q28217824 | ||
| Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance | Q33327324 | ||
| Safety of nonsteroidal antiinflammatory drugs and/or paracetamol in people receiving methotrexate for inflammatory arthritis: a Cochrane systematic review | Q33403087 | ||
| Leucopenia during sulphasalazine treatment for rheumatoid arthritis | Q33561793 | ||
| Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment | Q33668201 | ||
| Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen | Q33926455 | ||
| Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety | Q34123368 | ||
| CYP2D6 in the metabolism of opioids for mild to moderate pain | Q34178485 | ||
| Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids | Q34381920 | ||
| Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage | Q34387174 | ||
| In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate | Q48678324 | ||
| Potential drug interactions in patients with rheumatoid arthritis. | Q51048284 | ||
| Drug-induced agranulocytosis in the Berlin case-control surveillance study. | Q52881571 | ||
| Glucocorticoid use is associated with increase in HDL and no change in other lipids in rheumatoid arthritis patients. | Q53653844 | ||
| Stereoselective Inhibition of Methotrexate Excretion by Glucuronides of Nonsteroidal Anti-inflammatory Drugs via Multidrug Resistance Proteins 2 and 4. | Q53805550 | ||
| The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. | Q54381972 | ||
| Serious liver disease induced by infliximab | Q56452795 | ||
| Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen | Q71675085 | ||
| Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate | Q84127900 | ||
| Treating rheumatoid arthritis to target: recommendations of an international task force | Q34462557 | ||
| Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities | Q34549376 | ||
| Evaluation of the interaction between nonsteroidal anti-inflammatory drugs and methotrexate using human organic anion transporter 3-transfected cells | Q34597139 | ||
| Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis. | Q34758283 | ||
| Activation of autophagy protects against acetaminophen-induced hepatotoxicity | Q35631643 | ||
| The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis | Q35741946 | ||
| PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses | Q35842112 | ||
| Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis | Q36633307 | ||
| Inhibition of hepatic cytochrome P450 enzymes and sodium/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicity | Q36644296 | ||
| Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. | Q37156268 | ||
| Hypertension in rheumatoid arthritis. | Q37158219 | ||
| Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review | Q37740822 | ||
| Drug-drug interaction profiles of proton pump inhibitors | Q37770556 | ||
| Interleukin-6 and cytochrome-P450, reason for concern? | Q37997359 | ||
| Prevalence of drug interactions in hospital healthcare. | Q38042334 | ||
| The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. | Q38129037 | ||
| Drug-drug interaction software in clinical practice: a systematic review | Q38295919 | ||
| Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety | Q38364465 | ||
| Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force | Q38690324 | ||
| Proton pump inhibitors inhibit methotrexate transport by renal basolateral organic anion transporter hOAT3. | Q38954828 | ||
| Interaction Between Low-Dose Methotrexate and Nonsteroidal Anti-inflammatory Drugs, Penicillins, and Proton Pump Inhibitors | Q38971860 | ||
| Toxic and Endocrine Myopathies | Q39030487 | ||
| Apremilast: A Review in Psoriasis and Psoriatic Arthritis | Q39141679 | ||
| Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. | Q39796268 | ||
| Non-chemotherapy drug-induced agranulocytosis in a tertiary hospital. | Q40162078 | ||
| Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport | Q40226711 | ||
| Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies | Q40384138 | ||
| Neutropenia in patients with inflammatory arthritis treated with sulphasalazine | Q41155743 | ||
| In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. | Q41915866 | ||
| Antimalarials as a risk factor for elevated muscle enzymes in systemic lupus erythematosus | Q41916380 | ||
| Interleukins-12 and -23 do not alter expression or activity of multiple cytochrome P450 enzymes in cryopreserved human hepatocytes | Q42684280 | ||
| Inhibition of the healing of gastric ulcer by glucocorticoid and its relation to proinflammatory cytokines | Q43233521 | ||
| Dexamethasone reduces methotrexate biliary elimination and potentiates its hepatotoxicity in rats | Q43239463 | ||
| Characterization of methotrexate transport and its drug interactions with human organic anion transporters | Q44072251 | ||
| In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes | Q44585453 | ||
| Bone marrow aplasia following dipyrone treatment in a patient with Crohn's disease receiving long-term methotrexate | Q44970597 | ||
| Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations | Q45093086 | ||
| Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. | Q46119650 | ||
| The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine | Q46158721 | ||
| Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis | Q46711323 | ||
| P433 | issue | 4 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| psoriatic arthritis | Q511097 | ||
| P304 | page(s) | 511-521 | |
| P577 | publication date | 2020-02-12 | |
| P1433 | published in | Rheumatology International | Q15763689 |
| P1476 | title | Drug interactions in the treatment of rheumatoid arthritis and psoriatic arthritis | |
| P478 | volume | 40 |
Search more.